Variation of Serum Angiopoietin-2 in Renovascular Hypertensive Rats and Therapeutic Effect of Telmisartan

杨晓慧,卢新政,叶家欣,宗文纳,王俊宏,雍永宏,曹克将,黄峻
DOI: https://doi.org/10.3969/j.issn.1673-6583.2010.01.016
2010-01-01
Abstract:Objective:To study the effects of angiopoietin-2 in the development of hypertension and myocardial hypertrophy,and further to explore the effects of telmisartan on the myocardial hypertrophy and blood pressure in two kidney one clip (2K1C) hypertensive rats.Methods:24 Male Sprague-Dawly rats were randomly divided into control group (n=6),sham operation group (n=6),2 kidney 1 clip (2K1C) group (n=6) and 2K1C+telmisartan group(n=6).2K1C hypertensive model was established in Sprague-Dawly rats by chronic partial occlusion of left renal artery.Before and eight weeks after the operation,blood pressure was measured by arterial catheterization,the myocardial structure and function were detected by ultrasonography,and the serum angiopoietin-2 was evaluated by ELISA.Results:Eight weeks later,blood pressure and the thickness of left ventricle in 2K1C group were significantly higher than those in control and sham groups (P0.01,respectively).Compared with those in 2K1C group,blood pressure and thickness of left ventricle in 2K1C+ telmisartan group were significantly decreased (P0.01,respectively).Serum level of angiopoietin-2 was statistically increased in 2K1C group and was closely related to blood pressure and extent of myocardial hypertrophy,but was not decreased in 2K1C+telmisartan group(P0.05).Conclusion:Serum level of Angiopoietin-2 is increased in the renovascular hypertensive rats,and is positively related to myocardial hypertrophy.Telmisartan can reduce blood pressure and prevent myocardial hypertrophy,but can not decrease the angiopoietin-2 level,which indicates that it maybe not be associated with angiopoietin-2 level for telmisartan to prevent myocardial hypertrophy.
What problem does this paper attempt to address?